8-K: Glucotrack Completes Reverse Stock Split, Merges with Lokahi

Glucotrack, Inc. has implemented a 1-for-2 reverse stock split, effective October 23, 2026, and has completed its merger with Lokahi Therapeutics Inc., with pro forma financial information reflecting combined operations.

Summary

• Glucotrack, Inc. has executed a 1-for-2 reverse stock split, which became effective on October 23, 2026. This action reduces the number of outstanding shares from approximately 2,368,237 to 1,184,119.
• The company also completed a merger with Lokahi Therapeutics Inc. on July 14, 2026, with Lokahi becoming a wholly-owned subsidiary.
• Pro forma financial statements combine the historical results of Glucotrack and Lokahi, reflecting both the 1-for-15 reverse stock split (effective August 28, 2026) and the 1-for-2 reverse stock split (effective October 26, 2026).
• The combined entity reported a pro forma net loss of $19,699,822 for the six months ended June 30, 2026, and $28,135,308 for the year ended December 31, 2025.
• Significant intangible assets and goodwill were recognized as a result of the merger, totaling $25,400,000 and $15,631,064, respectively.
• The company has engaged in various financing activities, including bridge notes and warrants, and an interim PIPE financing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant financial losses and a reverse stock split, indicating potential financial distress and a need to boost share price.

Positives

• The merger with Lokahi Therapeutics Inc. creates a combined entity with pro forma total assets of $54,463,979 as of June 30, 2026.
• The merger resulted in the recognition of $25,400,000 in in-process research and development and other identified intangible assets, and $15,631,064 in goodwill.
• The company secured $4,450,000 in gross proceeds from initial bridge financing and an additional $3,500,000 from follow-on bridge financing.
• An interim PIPE financing raised $2,000,000 in proceeds.

Negatives

• The company reported substantial net losses: $19,699,822 for the six months ended June 30, 2026, and $28,135,308 for the year ended December 31, 2025 on a pro forma basis.
• The company has undergone two reverse stock splits (1-for-15 and 1-for-2) within a short period, indicating a strategy to artificially inflate the stock price.
• The pro forma net loss per share was significantly high: $(131.54) for the six months ended June 30, 2026, and $(473.94) for the year ended December 31, 2025.
• The company has substantial liabilities, including $11,738,734 in convertible notes at fair value and $1,090,165 in warrant liability as of June 30, 2026.
• The merger consideration involved issuing shares of Series A convertible preferred stock and common stock, valued at $34,290,345, which dilutes existing shareholders.

Risks

• The company's significant net losses and high net loss per share indicate a high risk of continued financial underperformance.
• The reverse stock splits suggest the company is struggling to maintain its stock price, which could lead to delisting from the Nasdaq Stock Market.
• The substantial amount of debt and convertible notes, along with associated interest expenses, poses a financial burden and risk of default.
• The integration of Lokahi Therapeutics Inc. may present operational challenges and risks associated with combining different business cultures and systems.
• The company has a history of financing through bridge notes and warrants, which can be costly and dilutive, indicating potential difficulties in securing traditional equity financing.

Future Outlook

The filing does not provide specific forward-looking statements or guidance regarding future financial performance. However, the pro forma financial information suggests significant ongoing losses, and the reverse stock splits indicate a focus on share price management.

Management Comments

• The filing includes pro forma financial information prepared to illustrate the effects of the merger between Glucotrack and Lokahi.
• Management believes the assumptions used in preparing the pro forma adjustments are reasonable.
• The pro forma financial information is not necessarily indicative of future financial position or operating results.

Industry Context

StockSavvy.ai notes that reverse stock splits are often employed by companies facing delisting risks or seeking to improve their stock's marketability. The merger with Lokahi Therapeutics suggests a strategy to consolidate or expand operations, potentially in the biotechnology or medical device sector, given Glucotrack's focus on glucose monitoring.

Corporate Governance

Stakeholder Impact

• Shareholders: The reverse stock split will reduce the number of shares held by shareholders proportionally, increasing their per-share ownership value but not their total equity value. The merger may dilute existing shareholders depending on the terms of consideration.
• Creditors: The company's significant losses and reliance on bridge financing may increase the risk for creditors.
• Employees: The financial performance and stock price volatility could impact employee morale and stock option values.

Next Steps

• The company's common stock began trading on a reverse stock split-adjusted basis on October 26, 2026.
• The transfer agent will send stockholders of record a transaction statement reflecting their holdings after the reverse stock split.
• Stockholders owning shares via a broker will have their positions automatically adjusted.

Key Dates

Recommendation

The company's persistent significant net losses, coupled with two reverse stock splits, indicate severe financial distress and a struggle to maintain market viability. While the merger aims to create a larger entity, the pro forma financials show continued substantial losses, and the financing activities are costly and dilutive. The recommendation is to sell due to the high risk of continued underperformance and potential for further share price decline.

Keywords

reverse stock split, merger, pro forma financials, net loss, Lokahi Therapeutics, Nasdaq, convertible notes, intangible assets